San Antonio, Texas
December 9-12, 2025
Booth #209
Connect with Caris Life Sciences at SABCS 2025
Caris Life Sciences® is proud to join the San Antonio Breast Cancer Symposium in San Antonio, Texas. Meet our team at booth #209 to discover the latest innovations in precision medicine and learn how our products and services are leading the molecular revolution.
Caris Abstracts and Poster Schedule
Caris’ strong presence at the SABCS 2025 demonstrates the clinical value of comprehensive molecular profiling and our commitment to transforming lives through research. Download the abstracts and presentation schedule, including a full list of summaries highlighting the research presented during SABCS 2025.
Oral
#GS1-08 Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx
Presenter: Joseph Sparano
Session: General Session 1
Time: 11:15 AM – 11:30 AM CST (Session: 9:30 AM – 12:00 PM CST)
Date: Wednesday, December 10, 2025
Location: Hall 1
Rapid Oral
#RF3-07 A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer
Presenter: Eleftherios Mamounas
Session: Rapid Fire 3
Time: 5:18 PM – 5:26 PM CST (Session: 4:30 PM – 5:30 PM CST)
Date: Wednesday, December 10, 2025
Location: Stars at Night 1-2
Spotlight Posters
#PD3-02 Personalized Acquired CDK4/6i Resistance: Associations with Baseline Characteristics Like Obesity in Real-World (RW) Clinical-Multiomics Data
Presenter: Kristin Zimmerman Savill
Session: Poster Spotlight 3: Emerging Paradigms of CDK Inhibitor and Antibody Drug Conjugate Resistance in Metastatic Breast Cancer
Time: 7:33 AM – 7:36 AM CST (Session: 7:00 AM – 8:30 AM CST)
Date: Wednesday, December 10, 2025
Location: 302 ABC
#PD3-11 Overcoming ADC Resistance: Payload Diversification as a Strategy for Sequential Therapy
Presenter: Jason Lee
Session: Poster Spotlight 3: Emerging Paradigms of CDK Inhibitor and Antibody Drug Conjugate Resistance in Metastatic Breast Cancer
Time: 8:12 AM – 8:15 AM CST (Session: 7:00 AM – 8:30 AM CST)
Date: Wednesday, December 10, 2025
Location: 302 ABC
#PD9-07 The Genomic, Transcriptomic, and Immune characterization of Metastatic Lobular Breast Cancer
Presenter: Guilherme Nader-Marta
Session: Poster Spotlight 9: Lobular Carcinoma
Time: 8:00 AM – 8:03 AM CST (Session: 7:00 AM – 8:30 AM CST)
Date: Thursday, December 11, 2025
Location: Hemisfair 1-2
#PD10-11 Differential Benefit to Elacestrant in a Large Cohort of ER+ Breast Cancer: Impact of ESR1 mutants and prior therapy
Presenter: George Sledge
Session: Poster Spotlight 10: Novel Combinations with Endocrine Therapy
Time: 8:12 AM – 8:15 AM CST (Session: 7:00 AM – 8:30 AM CST)
Date: Friday, December 12, 2025
Location: 301 ABC
Schedule a Meeting
Products at a glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure™ delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Cancer Seek
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric (ages 1-22) patients.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Complete Molecular Intelligence Report
The Caris Molecular Profiling Report delivers high impact results, including potentially relevant, actionable clinical information, in an easy-to-interpret format. Every report includes access to the MI Portal and the Clinical Trials Connector™, which matches each patient’s unique biomarker expression profile to open, pertinent clinical trial opportunities.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.